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Background. Candidemia is associated with mortality rates between 30 and 50%.
T2 magnetic resonance assay (T2MR) is a costly, rapid diagnostic technology that can
detect the five most common Candida species in blood with a sensitivity of 91% and
specificity of 99.4%. The clinical role of this tool remains unclear but this study shares
our clinical experience with T2MR.
Methods. We conducted a retrospective chart review of patients with T2MR
testing performed from April 25, 2017 through April 25, 2018. T2MR ordering was
restricted to Infectious Diseases pharmacists and physicians without specific ordering
criteria. Variables cataloged included the time between order and result in the medical chart, T2MR result, anti-fungal therapy and duration. Descriptive statistics were
reported on collected variables.
Results. Sixty-eight unique patients had T2MR ordered at least once during the
study time period. The median age was 62.5 years (interquartile range (IQR), 22–92)
and 42 patients (62%) were male. The median time between order and result appearing
in the medical chart was 6.21 hours (IQR, 3.55–40.93). Out of 72 tests performed, 4
were positive (2 for C. parapsilosis and 2 for C. krusei/glabrata). Only 1 of 4 T2MR positive patients had concurrent candidemia while 1 patient had suspected fungal endophthalmitis, 1 patient was managed for a fistula, and 1 patient had cutaneous candidiasis.
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Background. IA remains a leading cause of morbidity and mortality in immunocompromised children, and our understanding regarding epidemiology and outcomes
of IA are limited and based on adult studies.
Methods. We conducted a retrospective evaluation of cases of proven or probable
IA according to the 2008 EORTC/MSG criteria cared for at Boston Children’s Hospital
from 2007 to 2019. We collected data including demographics, clinical characteristics,
diagnosis modality, antifungal treatment, and survival. Survival curves over one year
were estimated using the Kaplan–Meier method and univariate and multivariate Cox
modeling was used to evaluate for risk factors for mortality.
Results. 67 patient cases were identified, 20 (30%) with proven IA and 47 (70%)
with probable IA. The mean age at diagnosis was 11.9 years (6 months–28 years).
Underlying conditions included hematopoietic-cell transplantation (HCT) in 45%,
cancer in 21%, and solid-organ transplantation in 18%. Pulmonary IA was the most
common (70.1%) presentation. Diagnostic modalities included positive microbiology
alone (18%), fungal PCR alone (1.5%), galactomannan alone (28%), and multiple
modalities for the remaining cases (52.5%). 44.8% of patients were neutropenic at
diagnosis and 78.5% of patients with malignancies were receiving chemotherapy.
Immunosuppressive drugs included glucocorticoids in 34.3%, calcineurin inhibitors in
31.3%, and IMDH inhibitors in 25.3%. Voriconazole was the most common treatment
used (72%). Twenty-two (33%) deaths occurred in the cohort attributable to IA (6 of
which underwent autopsies and 4 had histopathological confirmation) Most deaths
occurred in the BMT patients (15 patients, 45% of deaths). The 6 week mortality was
18% while the 12 week mortality was 25.4%. No antifungal or immunosuppressive
regimen had a statistically significant impact on mortality.
Conclusion. We demonstrate in our >10-year retrospective cohort analysis of
immunocompromised hosts that IA is associated with 49% all-cause mortality with
particular impact on the BMT population. No protective nor harmful association was
also noted with a particular antifungal or immunosuppressive regimen.

271. Fungal Diagnostic Studies in Histoplasmosis
Gayathri Krishnan, MD1; Margaret Power, BS1; J Ryan. Bariola, MD2 and
Ryan K. Dare, MD, MS1; 1University of Arkansas for Medical Sciences, Little Rock,
Arkansas; 2University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Session: 40. Fungal Diagnostics
Thursday, October 3, 2019: 12:15 PM
Background. Histoplasmosis (histo) is a common cause of invasive fungal infection in endemic regions and accurate diagnosis is difficult without direct tissue culture
or pathology. Indirect fungal antigen testing for various fungal pathogens is typically
performed to assist with diagnostic workup though cross-reaction can lead to difficulty
interpreting results. We aimed to evaluate the prevalence of positive antigen testing for
non-Histoplasma fungal pathogens in patients with proven invasive histo.
Methods. We performed a retrospective review of adult patients with proven
invasive histo from 2010–2018 at our institution. For inclusion purposes, histo was
confirmed by either fungal culture and/or cytology. Patient demographics, clinical
characteristics and results of fungal antigen testing for Histoplasma, Blastomyces,
Aspergillus, Cryptococcus and β-d-glucan were evaluated. Two different urine
Histoplasma antigen assays were used during the study period.
Results. 57 (31%) of 182 patients diagnosed with histo during the study period
had culture or cytology evidence of disease and were included in all further analysis.
Thirty-two (56%) of these patients were male, 35 (61.4%) were Caucasian and the mean
age was 50.1 years. HIV (20; 35%) and being on immunosuppressive medications (21,
37%) were common in this population. The majority of cases were classified as disseminated histo (40, 70%) followed by acute pulmonary (10; 18%) and chronic pulmonary
(7, 12%) disease. Results of fungal antigen testing are documented in the table. Chisquared analysis was performed.
Conclusion. There is a frequent cross reaction of non-Histoplasma fungal tests
in patients with histo. In our review, there was a high rate of cross reaction with
Blastomyces antigen, which can be confusing in regions where both pathogens coexist.
Elevation of β-d-glucan was high in these patients. Urine Histoplasma antigen sensitivity was higher with MiraVista testing for disseminated disease in our review. While
noninvasive fungal tests are helpful in diagnosis of these infrequent infections, clinicians must still maintain knowledge of the clinical differences between these fungal
pathogens and be aware of the limitations of these tests. A prospective study is needed
to better define differences between individual Histoplasma tests.
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Background. Over the years, the profile of patients with invasive pulmonary
aspergillosis (IPA) has extended beyond the commonly associated population with
hematologic malignancy (HM) and is now comprising patients with solid tumors and
patients with lung diseases. We therefore aimed to compare the clinical characteristics,
diagnostic approach and therapeutic outcome of IPA in cancer patients with hematologic malignancies vs. solid tumor (ST).
Methods. We conducted a retrospective study evaluating consecutive cases of
proven and probable IPA from March 2004 to December 2016 in a tertiary cancer
center. We included patients >18 years with an underlying ST, HM, or Hematopoietic
Cell Transplantation (HCT) within 1 year of IPA diagnosis.
Results. A total of 311 patients were analyzed: 225 had HM including HCT and 86
ST. Patients with ST were more likely to have had COPD (33% vs. 8%, P > 0.01) or other
underlying pulmonary diseases when compared with HM patients (76% vs. 43%, P <
0.01). Radiation therapy prior to the infection was also notably higher in the ST group
than the HM group (48% vs. 14%, P < 0.01). Patients with HM were more likely to have
received steroid (38% vs. 15%, P = 0.0001) and have concurrent neutropenia 37% vs.
2%, P < 0.0001). A. fumigatus was most commonly recovered in patients with ST than
in patients with HM (66% vs. 38%, P < 0.01). Monotherapy and voriconazole-based primary antifungal therapy were more often prescribed in patients with ST than in patients
with HM (87% vs. 56%, P < 0.0001 and 77% vs. 53%, P = 0.0002 respectively). Complete
or partial successful response to therapy was recorded in 66% of patients with ST compared with 40% in the HM group (P = 0.0001). IPA attributable mortality within 12
weeks was significantly higher in the HM than in the ST group (30% vs. 18%, P = 0.04).
Conclusion. Monotherapy with voriconazole were more often prescribed in patients
with ST than in patients with HM. Patients with ST had a better response to antifungal therapy and a lower IPA attributable mortality within 12 weeks compared with those
with HM.
Disclosures. All authors: No reported disclosures.
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Background. Detection of β-D-glucan (BDG) in serum is recognized as the
mycological evidence in the diagnosis of invasive fungal infection (IFI). However, its
diagnostic value in low prevalence of IFI has not been elucidated. We aimed to examine
the performance of BDG in hematology patients receiving antimold prophylaxis.
Methods. We retrospectively reviewed all BDG results performed for the purpose
of diagnosis or surveillance for IFI in hematology patients receiving posaconazole or
micafungin prophylaxis from January 2017 to February 2019 in a tertiary hospital. At
least two consecutive positive results of BDG were regarded as positive BDG. All the
episodes were classified into true-positive (TP, positive BDG with probable/proven IFI),
true-negative (TN, negative BDG without probable/proven IFI), false-positive (FP, positive BDG without probable/proven IFI), false-negative (FN, negative BDG with probable/proven IFI), and nonevaluable (could not be determined for the occurrence of
breakthrough IFI). When BDG test was performed in the setting of persistent fever ≥72
hours in spite of broad-spectrum antibiotics or with a suspicion of IFI, it was defined
as a diagnostic BDG episode, while others were defined as a surveillance BDG episode.
Results. Of a total of 140 episodes, 24 episodes were non-evaluable. Among 116
evaluable episodes, 75 received induction chemotherapy for acute leukemia or myelodysplastic syndrome, 35 underwent stem cell transplantation, and 10 had intensive
treatment for graft-vs.-host disease. There were three episodes of probable/proven IFI
(2.6%). Ninety-one (78.4%) were performed with diagnostic purpose, while 25 (21.6%)
were performed for surveillance. TP, TN, FP, and FN were 2 (1.7%), 91, 22, and 1,
respectively. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were 66.7%, 80.5%, 8.3% and 98.9%, respectively. PPV was 13.3% and 0%
in diagnostic and surveillance BDG episodes, respectively.
Conclusion. The PPV of BDG was low in hematology patients receiving antimold
prophylaxis, even in the diagnostic-driven episodes. The routine screening of BDG is not helpful, and the BDG test may be used for exclusion of IFI rather than for diagnosis in these patients.
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Of the negative tests, 1 patient had a false negative T2MR result despite blood cultures
growing C. glabrata. There was only 1 invalid test in our sample. Thirty-six patients
were initiated or maintained on anti-fungal therapy at the time of the T2MR test, with
micafungin being the most commonly prescribed anti-fungal agent. Negative T2MR
patients had a median anti-fungal therapy duration of 2 days (IQR, 0–16). Sixteen
patients (44%) had their anti-fungal therapy discontinued within 1 day of the negative
T2MR result. There were no patients with a negative T2MR result who subsequently
developed candidemia within 30 days after T2MR testing.
Conclusion. Our study showcases the benefit seen with T2MR in curtailing unnecessary anti-fungal exposure. Study limitations include a small cohort and evaluation at a single center. There is an opportunity for this technology to be utilized in
anti-fungal stewardship.
Disclosures. All authors: No reported disclosures.

